RPTX

Repare Therapeutics Inc.

A clinical-stage biotech company that designs targeted cancer drugs using a "synthetic lethality" approach — hunting the specific genetic weaknesses of tumor cells so treatments can kill cancer while sparing healthy tissue. Founded in 2016 by three cell-biology researchers in Montreal, the company's name is a play on "repair" and "pare," nodding to the DNA-repair pathways it exploits and the way it pares away cancer cells. Its experimental therapies include lunresertib and camonsertib, developed for cancers with certain DNA-repair defects.

No proxy statement recorded.